Tom - I agree that not all supplements are useful across the board for every person. However, for specific ailments many are extremely beneficial and. typically, there are studies to support those outcomes. The professionals who are certified to practice Functional Medicine work extensively with supplements once they have done specific testing that evaluates whether or not there is a functional deficiency. Often, a deficiency upstream manifests in an adverse health condition (downstream) and frequently, without Metabolic Profile Testing, the not always obvious as to the etiology.
A point that needs to be re-emphasized is that just taking supplements - even those we recommend here - may not work quickly when there are interferences at work that are unique to that individual. Our experience here over 10+ years indicates that some people respond very well to lifestyle and dietary changes and that supplements work very well to reverse afib... yet others, cannot tolerate any supplements at all, but follow the nutritional principles and also eliminate their afib. None of this happens in a month or two or in some cases even in six months or longer. Ribose wasn't even around when people such as Fran and Erling reversed their afib but it is a really important adjunct and should be given respect and consideration because the science behind energy production is irrefutable... that's just how the body works. Period.
From my ribose research archives... a few of many references...
BioEnergy patented their CorValen product...Patent 8,101,581
Use of D-ribose to treat cardiac arrhythmias
Abstract
D-ribose, given in doses of five to 15 grams daily, reduces or prevents the occurrence of atrial fibrillation in persons experiencing atrial fibrillation.
[
patft.uspto.gov]
Earlier there was a clip in a patent application that indicated:
BioEnergy's patent work with ribose is available online...
Here's a clip from the patent relevant to the function of ribose and ATP levels.
BRIEF DESCRIPTION OF THE INVENTION
The present invention provides a method for reducing the period of tissue function recovery following ischemic insult comprising perfusion of the tissue with a solution incorporating a mixture of adenine and a physiologically-acceptable pentose or pentitol, preferably ribose. This method shortens the period required for substantially complete recovery of ATP levels from about ten days to about 1-2 days. Furthermore, with respect to cardiac tissue, the return of heart function (diastole) closely parallels the return of ATP levels.
Adenine and ribose are infused in an amount effective both to restore and maintain the tissue ATP levels at a level substantially equal to that present in the preischemic tissue. Although it was expected that once an amount of adenine and ribose effective to restore the ATP level had been infused, the level would be maintained by the tissue, it was surprisingly observed that the effects of ischemia, and the accompanying net ATP catabolism are not immediately reversed by the restoration of ATP levels and tissue function. Thus, both ATP levels and cardiac function were observed to fall following premature cessation of the adenine-ribose infusion. Therefore, the present method also comprises continuing the infusion for the full duration of the ischemic effects, e.g., until the net catabolism of ATP has ceased, and not merely to the extent necessary to restore the tissue ATP levels.
Adenine/ribose infusion is a physiologically innocuous procedure. The only undesired effect is a tendency to lower blood sugar, a condition which is easily monitored and corrected. Therefore, the method of the present invention need not be limited to extreme situations such as those accompanying cardiac surgery, but can be extended to any situation in which hypoxia threatens tissue function.
This report from CorValen Labs
Gross, G, J Auchampac. Role of ATP dependent potassium channels in myocardial ischaemia. Cardiovasc Res 1992; 26:1011-1016.
Recently, a class of potassium (K) channels has been discovered which are regulated by the intracellular level of ATP. These channels have been termed ATP dependent K channels (KATP) and have been found to exist in the heart, skeletal muscle, pancreatic beta cells, brain, and smooth muscle. In this article, we discuss the function of the KATP channel in the ischaemic myocardium and present evidence to suggest that activation of these channels may, on one had result in a marked cardioprotective effect from reversible or irreversible electrical, functional or biochemical change, or on the other hand, have the potential to produce electrical instability and a proarrhythmic effect. The therapeutic potential of potassium channel modulators is also discussed.
A reference to potassium channels regulated by the intracellular levels of ATP and a potential to produce electrical instability and proarrhythmic effect is also included at the end.
====
This from CorValen's website
Selected list of Clinical Studies:
Coronary Artery Disease
A randomized, double blind, placebo controlled clinical trial with 20 patients with coronary artery disease and stable angina (chest pain).
RESULTS:
• D-Ribose increased treadmill walking time to ST segment depression; nearly 20% greater improvement versus placebo
• After 3 days, also improved the heart's tolerance to ischemia.
Coronary Artery Disease/ Congestive Heart Failure
Prospective, randomized, double blind, placebo controlled, crossover design study to assess effects of D-ribose supplementation in 15 patients with coronary artery disease and congestive heart failure (Class II – III).
RESULTS:
• D-Ribose led to an enhancement of atrial contribution to left ventricular filling, a smaller left atrial dimension, and a shortened E wave deceleration by echocardiography
• Resulted in a 12% increase in quality of life as measured on validated scale.
Congestive Heart Failure (CHF)
Clinical trial with 14 congestive heart failure patients (NYHA Class II – III) was enrolled in a double blind, placebo controlled, crossover design. Maximal cycle ergometry with gas exchange was monitored pre- and post- each treatment period.
RESULTS:
• With exercise, D-ribose-treated CHF patients maintain better ventilatory efficiency, a strong predictor of heart failure survival
• Also improved VO2max, reduced shortness of breath, increased exercise tolerance, and increased hypoxic threshold vs. placebo.
Open Heart Surgery A randomized, double blind clinical trial with 27 open heart patients.
RESULTS:
• Ejection fraction in placebo group significantly depressed following 7-days of post-surgical recovery
• At 7 days, 80% of placebo group demonstrated decline, whereas only 20% of the D-ribose group experienced decline.
Coronary Artery Disease
A comparison of the results of 143 patients receiving D-ribose as an oral “pre-op” versus 40 historical patients following a similar protocol, without supplementation.
RESULTS:
• “Off” pump cardiopulmonary bypass with supplemental ribose resulted in no peri-operative deaths and no post-operative myocardial infarctions
• Ribose treated patients showed a 43% improvement in cardiac index (cardiac output/surface area) vs. 13% with historical controls without ribose.
Congestive Heart Failure
An 8-week open-label clinical trial with 15 congestive heart failure patients (Class III (9) and IV (6)) undergoing cardiopulmonary testing.
RESULTS:
• O2 uptake efficiency, stroke volume (O2 pulse), and ventilatory efficiency, the most powerful predictor of patient survival, were significantly improved following supplementation with D-ribose.
Chronic Fatigue Syndrome/ Fibromyalgia
Open-label uncontrolled pilot study involving 41 participants.
RESULTS:
• Subjective patient questionnaires revealed significant improvement in all five visual analog scale (VAS) categories: energy; sleep; mental clarity; pain intensity; and well-being
• Improvement in patients' global assessment also demonstrated
• Approximately 66% of patients experienced significant improvement, with an average increase in energy on the VAS of 45% and an average improvement in overall well-being of 30% (p < 0.0001).
[
www.corvalen.ca]
Then there is the whole series of interviews about Ribose at Richard Passwater, PhD's website..
Several experts including John St. Cyr, MD PhD ribose researcher are interviewed.
If one doubts anything about ribose, this is the place to read more. Just Google Passwater Ribose and all the interviews come up.
I have more info, but this should be sufficient.
=========
Multiple Studies Indicate Benefit of D-Ribose For Cardiac Patients
Minneapolis, MN - August 12, 2005 - Cardiologists and heart patients alike are looking for a safe and effective way to treat the symptoms of coronary disease. According to a growing body of research, D-ribose offers just such a treatment naturally and without side effects.
"Hearts that are stressed by disease or cardiac events share a common characteristic: they are starved for cellular energy," said John St. Cyr, M.D., Ph.D., medical director of Valen Labs, Inc. "D-Ribose is an integral part of the energy-producing process. By adding supplemental D-ribose, the heart is able to speed the process of rebuilding energy. As a result, patients feel better with less fatigue, experiencing an increased quality of life."
Consider the following four studies:
In a randomized, placebo controlled, crossover study of 15 patients with Class C CHF, researchers at the University of Utah's Department of Internal Medicine showed that oral D-ribose therapy for eight weeks improved myocardial performance index and ventilatory efficiency while preserving exercise capacity. Myocardial performance index, ventilatory efficiency, and exercise capacity are powerful predictors of survival in patients with CHF. After using D-ribose for eight weeks all patients either maintained or showed improvement in indicators that can predict survival for heart failure patients, leading researchers to conclude that D-ribose should be considered as an adjunctive therapy for advanced heart failure patients.
A second study, conducted by Aurora Denver Cardiology Associates, Denver, Colorado, also investigated the effect of D-ribose on ventilatory efficiency. As in the earlier study, 15 Class III and IV CHF patients were given D-ribose orally for eight weeks as adjunctive therapy to their existing treatment. Patients treated with D-ribose showed significant, positive improvement in ventilatory efficiency, oxygen uptake efficiency, and stroke volume, the amount of blood the heart pump with each beat.
In the third study, researchers at the University of Bonn in Germany investigated the role of D-ribose on diastolic function following ischemic events. A prospective, randomized, double blind crossover designed study of 15 patients demonstrated that the addition of supplemental D-ribose improved diastolic function, increased physical function and added to patient quality of life.
In a study conducted at Saddleback Medical Center in Orange County, California, researchers studied the benefits of D-ribose in patients undergoing "off" pump coronary artery revascularization. Of the 44 patients participating in the study, 24 consumed D-ribose pre-operatively, while 20 did not. Those treated with D-ribose demonstrated a 49% greater increase in cardiac indices compared with the control group.
Hospitals and cardiologists across the country are recognizing the benefits of D-ribose, and are offering it to their patients. Valen Labs offers D-ribose to as a cardiovascular therapy under the brand name CORvalen
Bioenergy Inc. is a privately-held, Minneapolis-based life sciences company whose core technology lies in the development and commercialization of products based on the physiological benefits of D-ribose in health and wellness. Bioenergy's clear mission is to develop products that increase the quality of its customers' lives by improving the function of their hearts, muscles, and other body tissues. Valen Labs, Inc, its subsidiary, markets ribose-based products to the functional food and clinical nutrition markets. These products include CORvalen, a clinical nutrition product giving metabolic support to heart patients; and CORvalenM, a dietary supplement that helps relieve myalgia, muscle soreness, cramping and fatigue.
=======
CARDIOVASCULAR DISEASE - D-Ribose, Energy
Reference: "D-Ribose as a Supplement for Cardiac Energy Metabolism," Pauly DF, Pepine CJ, J Cardiovasc Pharmacol Therapeut, 2000;5(4):249-258. (Address: Dr. Daniel F. Pauly, P. O. Box 100277, Univ Florida College of Med, 1600 S.W. Archer Rd, Gainesville, FL 32610, U.S.A.)
Summary: D-Ribose is a naturally occurring monosaccharide. Monosaccharides have the empiric formula (CH2O)n, consist of polyhydroxy carbon chains and have a single carbonyl oxygen. It is hypothesized that under certain cardiac conditions, nucleotides (in particular ATP, ADP and AMP) are degraded and lost from the heart. The heart’s ability to re-synthesize ATP is then limited by the supply of D-ribose, which is a necessary component of the adenine nucleotide structure. Recent reports have shown that D-ribose can increase tolerance to myocardial ischemia. In patients with stable coronary artery disease, there has been improvement in time to exercise-induced angina and electrocardiographic changes. D-Ribose has no significant effects on cardiac hemodynamics. It does not influence coronary blood flow or myocardial oxygen consumption. D-Ribose is not a preferred substrate for energy production in the heart. Its beneficial effects have been attributed to replenishing ATP through increased 5-phospho-D-ribose 1-pyrophosphate (PRPP) availability and increased de novo ATP synthesis. D-Ribose plays a role in providing PRPP and adenine nucleotide repletion in reversibly injured myocardium and in the related models of hypertrophy and regional infarction. The amount of cardiac preservation that might occur from supplementation may depend on the severity of cardiac insult, the duration of the injury, and the particular functional index measured. The contribution of metabolic repletion of D-ribose should be most beneficial when PRPP is the primary limitation. This appears to be the case early in injury and late in recovery. The available data suggest that either oral or intravenous administration of D-ribose may have clinical utility in a wide variety of cardiovascular conditions, including ischemia, hibernation, hypertrophy and cardiomyopathy. D-Ribose may have benefit by increasing the speed of ATP repletion and enhancing functional recovery after injury.
CARDIOVASCULAR DISEASE - Conditionally Essential Nutrients, Coenzyme Q10, L-Carnitine, Propionyl-L-Carnitine, L-Arginine, Taurine, Alpha-Lipoic Acid, Betaine, Chondroitin Sulfate, Glutamine, D-Ribose, Hypertension, Hyperlipidemia, Lipoprotein(a), Heart Failure, Myocardial Infarction, Angina Pectoris
Topic: Role of Conditionally Essential Nutrients in Cardiovascular Disease Therapy
Reference: “Supplemental conditionally essential nutrients in cardiovascular disease therapy,” Kendler BS, J Cardiovasc Nurs, 2006; 21(1): 9-16. (Address: Department of Biology, CMSV Campus, Manhattan College, Riverdale, NY 10471, USA.
Summary: In this article, studies related to the role of conditionally essential nutrients as they relate to cardiovascular disease (CVD) and CVD risk factors are reviewed. All the studies included in the review are prospective, randomized, double-blind, and placebo-controlled, dealing with human subjects and CVD that have been published in peer-reviewed publications. The authors give some background about conditionally essential nutrients (CENs). CENs are organic compounds produced in the body that under healthy circumstances, are produced in sufficient quantities to meet physiological needs. However, during certain stages in life or in certain pathological conditions, CENs may not be produced in adequate amounts, rendering them essential dietary nutrients, akin to vitamins. The author summarizes studies related to the following CENs and their role in CVD: coenzyme Q10, l-carnitine (CAR), propionyl l-carnitine (PCAR), and l-arginine (ARG). Taurine is discussed only briefly due to paucity of data involving human subjects, although the animal and in vitro data is promising. As a whole, these CENs have been shown to be clinically beneficial with regards to chronic heart failure, myocardial infarction, angina pectoris, hypertension, hyperlipidemia, and lipoprotein(a). Specifically, coenzyme Q10 was found to be effective as an adjunctive therapy in patients with acute myocardial infarction, coronary artery disease, coronary heart disease, and non-insulin-dependent diabetes mellitus. Coenzyme Q10 was also found to improve stroke volume, cardiac output, ejection fraction, cardiac index, and end-diastolic volume index. In addition, decreases in total cardiac events, various markers of lipid peroxidation, lipoprotein(a), systolic and diastolic blood pressure, and hemoglobin A1C were found with coenzyme Q10 supplementation. Numerous studies reviewing CAR are discussed, which include the successful use of CAR in patients with moderate cardiac insufficiency, moderate to severe heart failure, chronic stable angina, exercise-induced angina, and acute anterior myocardial infarction. In addition, it was found to have favorable effects on heart rate, systolic and diastolic blood pressure, blood lipids, cholesterol, left ventricular function, and lipoprotein(a). PCAR was found to be beneficial in patients with CHF, intermittent claudication and prevention of intravascular clotting. While a recent study raises serious questions about the use of l-arginine in patients who have recently experienced acute myocardial infarction, the studies reviewed in this article demonstrate the effectiveness of l-arginine in healthy subjects and patients with risk factors for CVD (such as hypercholesterolemia), in inhibiting platelet aggregation, improving endothelial-dependent vasodilation, reducing monocyte-endothelial adhesion resulting in decreased atherogenesis, reducing plasma endothelin vasodilation, inducing greater pain-free and total walking distance in intermittent claudication, improving flow-mediated dilation of the brachial artery, decreasing LDL, increasing the HDL/LDL ratio and improving forearm blood flow, walking distance, and subjective symptoms in chronic heart failure (CHF) patients. The findings of this review suggest that CENs, which have demonstrated effectiveness and safety in numerous clinical trials, may have very critical roles to play in the treatment of patients with or at risk of developing CVD. Additional controlled, clinical trials are needed to further investigate and understand the role of CENs in CVD.
CORONARY ARTERY/HEART DISEASE - Ribose and Exercise-Induced Myocardial Ischemia
Reference: "Effects of Ribose on Exercise-Induced Ischemia in Stable Coronary Artery Disease", Pliml, Wolfgang, et al, The Lancet, August 29, 1992;340:507-510.
Summary: There is evidence that the pentose sugar ribose stimulates ATP synthesis and improves cardiac function. Twenty men with coronary artery disease underwent 2 symptom-limited treadmill exercise tests on 2 consecutive days. The 20 men studied were between 40 and 69 years of age. Patients were randomly allocated 3 days of treatment with placebo or ribose at 60 gms daily in 4 doses by mouth. After day 5, exercise testing was repeated, and it was found that a treadmill walking time until 1 mmST-segment depression was significantly greater in the ribose than in the placebo group. The groups did not differ significantly in time to moderate angina. In the ribose-treated group, the changes from baseline to day 5 in both time to ST depression and time to moderate angina were significant. The authors conclude that, in patients with coronary artery disease, the administration of ribose by mouth for 3 days improved the heart's tolerance to ischemia. The authors conclude that ribose can effectively influence cardiac energy and metabolism. Further studies are warranted to see if this drug may be beneficial as an adjunctive therapy for myocardial ischemia. Metabolic cardioprotection with ribose might be especially advantageous for patients undergoing heart surgery, or in unstable coronary artery disease.
FIBROMYALGIA - Ribose
Reference: "Benefit of Ribose in a Patient With Fibromyalgia," Gebhart B, Jorgenson JA, Pharmacotherapy, 2004;24(11):1646-1648.
Summary: This is a case report of a 37-year-old female surgeon who developed extensive fibromyalgia and could not perform her job, with the increasing symptoms of intense musculoskeletal pain and stiffness, mental "cloudiness", bouts of diarrhea and sleep disturbance. She was placed on ibuprofen at 800 mg, twice daily, valdecoxib at 10 mg, once daily, diphenhydramine at 50 mg-acetaminophen at 1,000 mg at bedtime and physical therapy once daily. This regimen had limited benefit and further impaired her ability to perform her job. Approximately 7 months later, she began taking CORvalen (Bioenergy, Inc., Ham Lake, MN), a ribose-based product. She took 5 g of CORvalen mixed in water, twice daily. She experienced no adverse effect, and after 14 days, she reported a decrease in her symptoms. She noted improvement in sleep, mental alertness and a marked decrease in joint pain, and normal stools. After an additional month of CORvalen therapy, she reported near-normal functioning with a major reduction in her symptoms. After another month of CORvalen and feeling "normal," the patient stopped the drug. Within 7 days, the symptoms returned. She resumed taking CORvalen at the same dose as before, and there was a major reduction in her symptoms again occurring within 14 days. She noted continued benefit for another month and then stopped the product, with a reemergence of her symptoms. The CORvalen was started for a third time and the patient’s symptoms subsided. She remains on the CORvalen product and is satisfied. Ribose is a simple carbohydrate that plays a role in high-energy phosphate and nucleic acid synthesis. After ischemia or hypoxia, myocytes have reduced levels of adenosine 5'-triphosphate (ATP) and total adenine nucleotides. In patients with chronic hypoxic conditions, the cellular energy charge may never be fully regained. These cells have the capacity to regenerate ATP, but the pentose phosphate pathway of glucose metabolism utilized in the formation of ribose that is needed to drive the regenerative process is slow in both heart and skeletal muscle due to poor expression of specific rate-limiting enzymes. Supplemental ribose has been shown to enhance the synthesis of adenine nucleotides, rebuilding depressed energy pools in both the heart and skeletal muscle after ischemic or hypoxic insult. Ribose bypasses the rate-limiting enzymatic steps of the pentose phosphate pathway and accelerates the formation of ATP and subsequent tissue recovery. Initially, supplemental ribose is converted to ribose-5-phosphate, and then forms 5-phosphoribosyl-l-pyrophosphate, which is a key molecule in the synthesis of ATP through the de novo purine nucleotide pathway.
EXERCISE - Ribose
Reference: "The Effects of Four Weeks of Ribose Supplementation on Body Composition and Exercise Performance in Healthy, Young, Male Recreational Bodybuilders: A Double-Blind, Placebo-Controlled Trial," Van Gammeren D, Falk D, Antonio J, Curr Ther Res, August 2002;63(8):486-495.
Summary: Ribose is a pentose sugar that is present in ribonucleic acids, riboflavin, nucleotides and adenosine triphosphate. In studying 20 male recreational body builders who were between 18 and 35 years of age, subjects were randomized to a ribose-supplemented group at 10 g/day in powder formulation or a dextrose placebo group followed by heavy-resistance training designed to increase skeletal muscle mass. Twelve subjects completed the study. The ribose-supplemented group had a significant pretreatment-to-posttreatment increase in the total work performed, whereas the placebo group did not change significantly. In the ribose-supplemented group, there was a significant increase in 1-repetition maximum-strength in the bench press, whereas the placebo group did not change significantly. There were no treatment-to-posttreatment within-group or between-group differences found for any measures of body composition or the 24-hour dietary data.
===
This interview addresses fibromyalgia, but the physiology is the same for ATP production... heart cells or muscle cells.
The Experts Speak
Fibromyalgia and Ribose
James Jorgenson, M.S.
Department of Pharmacy Services
University Hospital
50 North Medical Drive, Room A-050
Salt Lake City, UT 84132 USA
“Benefit of Ribose in a Patient With Fibromyalgia”
Pharmacotherapy, 2004;24(11):1646-1648. #42747 (03/2005)
Kirk Hamilton: Could you please share with us your educational background and current position?
James Jorgensen: I completed my B.S. in pharmacy from the University of Minnesota in 1977 and my Masters of Science in 1980. I completed an ASHP Accredited Residency in Hospital Pharmacy at United and Children’s Hospital in St. Paul, Minnesota concurrent with my masters degree.
Currently, I am the Director of Pharmacy Services for the University of Utah Hospitals and Clinics and the Associate Dean for Clinical Affairs at the University of Utah College of Pharmacy in Salt Lake City, Utah.
KH: How did you become interested in using ribose for fibromyalgia?
JJ: I first heard about ribose during my residency when it was being pioneered by Dr. John Foker for use in cardiac surgery patients at the University of Minnesota. More recently, ribose has been appearing in the medical literature in relation to its utility in treating congestive heart failure. We have been engaged in a double-blind crossover clinical trial using ribose in stage II and III CHF patients at the University of Utah. From our preliminary results, we have been encouraged by its improvement in heart function. Results of that study will be presented by Mark Munger, PharmD, and his investigative team at the March, 2005 American College of Cardiology conference in Orlando. Given its mechanism of action on enhancing ATP production, we thought it may have application in other conditions where depressed ATP levels are present such as fibromyalgia.
KH: Can you tell us a little about CORvalen, its hypothesized mechanism of action, and why you started with 5 g twice daily?
JJ: CORvalen contains D-Ribose, a naturally occurring sugar. Ribose is the core component of ribonucleic acid (RNA) and is also a key component of adenosine triphospate (ATP). At the cellular level, ATP is responsible for energy transfer and it is this process that we felt could be impacted by exogenous ribose supplementation in fibromyalgia patients. Adenosine is comprised of one molecule of ribose and one molecule of adenine. When coupled with three phosphate molecules, ATP is formed. Energy is created when the bond holding one of the phosphate molecules is broken. This results in adenosine diphosphate and inorganic phosphate. In aerobic states when plenty of oxygen is present, this bond can quickly be reformed to produce ATP. However, if oxygen is lacking (anaerobic metabolism) creatine phosphate (CrP) will be utilized for the phosphate that is required to reform ATP from ADP. If the cellular sources of CrP are depleted, the cell can fall back on a third mechanism to produce ATP called the myokinase reaction. In this reaction, two ADP molecules are used to make one ATP and one adenosine monophosphate (AMP). The body must keep ATP/ADP/AMP ratios in the proper balance if cellular function is to be maintained. Ribose as a core component of adenosine must be present in sufficient quantities for these mechanisms to work. Unfortunately, ribose supplied in food is insufficient to support demands during high stress periods or high intensity exercise. The body manufactures ribose from glucose but this process is quite slow and inefficient. The hypothesized mechanism of action for ribose centers on supplemental or exogenous ribose being able to augment the body’s natural production of ribose and assist in synthesis of ATP to support cellular energy needs.
We selected a 5 gram dose twice daily based on the available cardiac literature. This seemed to be the most common dose studied. However, we are currently in the final stages of designing a clinical trial to document ribose efficacy in fibromyalgia patients and we are planning on using 5 grams three times daily for the study patients. We think that it may be beneficial in fibromyalgia patients to build up ATP production as quickly as possible.
KH: Are there any other components of CORvalen besides ribose?
JJ: The CORvalen product contains only D-Ribose. However, Valen Labs also has a CORvalenM product targeted toward fibromyalgia patients that in addition to ribose also contains magnesium and malic acid. There is some evidence that these entities may also be beneficial in fibromyalgia patients.
KH: Can you tell us the clinical course of your patient before, during and after using the CORvalen product?
JJ: The patient described in our case study is a 37 year old female. She is a surgeon and her fibromyalgia symptoms were affecting her abilities to perform her operative duties. She was experiencing episodes of intense musculoskeletal pain and stiffness, mental “cloudiness”, bouts of diarrhea and sleep disturbances. Her treatment regimen of non-steroidal anti-inflammatory agents, diphenhydramine, acetaminophen and physical therapy was providing only limited relief. In addition to her regular therapy, we added CORvalen 5 grams mixed in water twice daily. After 14 days of CORvalen therapy, she reported a decrease in her symptoms. She noted an improvement in joint pain, mental alertness, sleep patterns and normal stools. Her improvement continued and after one month of CORvalen therapy she indicated a significant decrease in symptoms and near normal functioning. After another month of CORvalen therapy, the patient felt “normal” and decided to discontinue therapy. Within 7 days, she regressed to her previous level. She reported joint pain, sleep disturbances, morning stiffness, trigger point flares and diarrhea. She again started CORvalen therapy at 5 grams twice daily. Within 14 days she reported major reductions in symptoms. She continued on CORvalen for another month and again stopped the therapy. She experienced a similar reoccurrence of symptoms which again improved when CORvalen therapy was reinitiated. She is currently continuing with CORvalen therapy and feels that her symptoms are controlled.
KH: Were there any side effects as a result of the CORvalen?
JJ: We did not see any side effects with this patient. In terms of side effects the most common would be gastrointestinal and blood sugar alterations. Literature reports indicate that extremely large doses of ribose, in the area of 60 grams daily, are needed to produce gastrointestinal side effects. With blood sugar, even though ribose is a sugar, it can cause a transient and slight drop in blood sugar (2 to 5 points). With most patients this is insignificant without demonstrating symptoms but in a very “brittle” insulin dependant diabetic, this could be a concern and should be watched. A final concern would be ribose use in oncology patients. There is some thought that supplying ribose and elevating ATP levels could result in enhanced tumor growth. Although there are no literature reports to support or refute this theory, we err on the side of caution and do not recommend ribose use in patients that also have active cancer.
KH: Do you have any further understanding of how CORvalen might work in fibromyalgia patients?
JJ: The cause of fibromyalgia remains unknown but it has been associated with stress, trauma, hormone deficiency disorders, alteration in neural chemistry, anemia, parasites and infections. The continued muscular pain and stiffness that fibromyalgia patients manifest led us to consider ribose supplementation. It has been demonstrated that patients with fibromyalgia have reduced exercise capacity and muscles that lack contractile force and endurance. Examination of skeletal muscle in fibromyalgia patients has shown reduced blood flow, changes in capillary wall thickness and structural changes to the mitochondria that contribute to localized hypoxia, decreased oxidative phosphorylation and ultimately lower ATP synthesis and altered ATP/ADP/AMP ratios. As previously discussed, depressed ATP levels result in altered energy metabolism of the cell’s integrity and functionality which leads to further metabolic disruption and ultimately muscle soreness and stiffness. Ribose supplementation could play a part in restoring normal ATP levels and reversing this metabolic cascade. While ribose supplementation would not “cure” fibromyalgia patients, if mechanisms producing alterations in ATP are a contributing factor to the cause of this disease then ribose could help to bring treatment “down another level”. Traditional drug therapy is focused on symptom control or relief. Ribose therapy could potentially prevent symptoms from appearing and thereby provide a better quality of life to these patients.
Source: Vitasearch
=====
Jackie